Alentis Therapeutics is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing a pipeline of Claudin-1 (CLDN1) targeted medicines. The company aims to create first-in-class therapies that address unmet medical needs by targeting CLDN1, a key player in various pathological processes.
